CTOs on the Move

Massage Heights

www.massageheights.com

 
The massage franchise started in 2004 and has grown to more than 120 Retreats throughout North America by providing personalized wellness treatment options through therapeutic massage and skincare services. Massage Heights is a family-owned massage and wellness franchise dedicated to elevating the lives of others by providing Members and Guests with professional, affordable and resort-quality massage, skincare and wellness services.
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details

Similar Companies

CanaFarma Corporation

Canafarma Corp. has the technology and products that can be offered to the market. Successful experience with chewing gum Yooforic, the flagship product of the company — this confirms! Our product is in demand, so right now we are ready to expand the range, offer new products and enter a new level of development of both production facilities and the distribution network.

Absolute Home Health Care

Absolute Home Health Care is a Kissimmee, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mobilewheelchairs

Mobilewheelchairs is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medical Treatment Systems

Medical Treatment Systems is a Raleigh, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Accord BioPharma

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.